Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards
SHENZHEN, China, Dec. 30, 2025 /PRNewswire/ -- On December 5, 2025, Dr. Lu Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards. Dr. Lu Xianping delivers his remarks at the award ceremony. This recognition honors his outstanding contributions to advancing new-quality...
Bioelectric Toothbrush Offers New Approach with 6x Plaque Removal
Clinically validated microcurrent technology now available in the U.S. market SAN FRANCISCO, Dec. 29, 2025 /PRNewswire/ -- Great Gums Inc. today announced the U.S. launch of its bioelectric toothbrush, a clinically validated oral care device that delivers safe microcurrents to remove plaque from hard-to-reach areas where traditional bristles cannot effectively clean. Great Gums bioelectric toothbrush...
HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation
HONG KONG, Dec. 29, 2025 /PRNewswire/ -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on 15 December 2025, a significant initiative to deepen collaboration between Hong Kong and the Chinese Mainland in the fields of medicine and medical physics. During the ceremony, Dr. Walton LI, Chief...
Adventures in DMPK: Viva Biotech’s One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology platform that covers this end-to-end modality range, supporting programs from in vitro ADME assays...
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by...
SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor) in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer (Study...
Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy
TAIPEI and SAN DIEGO, Dec. 29, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. (TPEx: 6492, hereafter "Senhwa"), today announced another major milestone. The Company's first-in-class...
Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore
SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic, Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthcare more accessible to families and individuals. ...
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"). The two...
Festive Season Isolation: How Eczema Is Keeping Singaporeans From Gatherings
Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period traditionally associated with connection and joy. SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- For many, the festive season is marked by reunions, shared meals and long-awaited gatherings. For Mr Li, however, it often comes with apprehension. Festive periods tend to disrupt...
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy product, CT0596. The applications seek...
